These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 12009236)
1. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Reinmuth N; Brandt B; Semik M; Kunze WP; Achatzy R; Scheld HH; Broermann P; Berdel WE; Macha HN; Thomas M Lung Cancer; 2002 Jun; 36(3):265-70. PubMed ID: 12009236 [TBL] [Abstract][Full Text] [Related]
2. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related]
4. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Ma S; Shen L; Qian N; Chen K Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301 [TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients. Pujol JL; Boher JM; Grenier J; Quantin X Lung Cancer; 2001; 31(2-3):221-31. PubMed ID: 11165401 [TBL] [Abstract][Full Text] [Related]
6. Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Massaron S; Cataldo I; Oldani S; Iurlo A; Caldiera S; Bombardieri E Int J Biol Markers; 1999; 14(2):92-8. PubMed ID: 10399628 [TBL] [Abstract][Full Text] [Related]
7. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer. Jiang AG; Chen HL; Lu HY BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656 [TBL] [Abstract][Full Text] [Related]
9. The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. Zhang L; Liu D; Li L; Pu D; Zhou P; Jing Y; Yu H; Wang Y; Zhu Y; He Y; Li Y; Zhao S; Qiu Z; Li W BMC Cancer; 2017 Feb; 17(1):96. PubMed ID: 28152979 [TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum tumor markers in patients with lung cancer. Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM Respiration; 2002; 69(1):25-9. PubMed ID: 11844959 [TBL] [Abstract][Full Text] [Related]
12. [Variations in Serum CEA and CYFRA21-1 Levels Before and After Surgery Facilitate Prognosis of Non-small Cell Lung Cancer Patients]. Duan X; Cui Y; Gong M; Tian F; Shi G; Wu B; Liu M; Guo J; Kong Y Zhongguo Fei Ai Za Zhi; 2015 Jun; 18(6):358-64. PubMed ID: 26104892 [TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Muley T; Dienemann H; Ebert W Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383 [TBL] [Abstract][Full Text] [Related]
14. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607 [TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors in patients with stage III and IV non-small cell lung cancer]. Song LH; Song XR; Liu MQ; Zhang XQ; Zheng L; Li XJ; Liu PX Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):345-8. PubMed ID: 15312344 [TBL] [Abstract][Full Text] [Related]
16. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer. Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728 [TBL] [Abstract][Full Text] [Related]
17. Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Nieder C; Andratschke N; Jeremic B; Molls M Anticancer Res; 2003; 23(6D):5117-23. PubMed ID: 14981976 [TBL] [Abstract][Full Text] [Related]
18. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers. Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756 [TBL] [Abstract][Full Text] [Related]
19. Combined detection of estrogen and tumor markers is an important reference factor in the diagnosis and prognosis of lung cancer. Bai Y; Shen W; Zhu M; Zhang L; Wei Y; Tang H; Zhao J J Cell Biochem; 2019 Jan; 120(1):105-114. PubMed ID: 30216488 [TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer. Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]